Studienlage · Detail
Keine Richtungsangabe
GRADE
Moderat
21 Zitate
StichprobeMeta-Analyse
KontrolleNicht-Cannabis-Konsum
DesignMeta-Analyse
Kernaussage
Cannabiskonsum zeigte einen signifikanten, aber sehr kleinen Risikobeitrag für Gebärmutterhalskrebs sowie schwache Hinweise für Kehlkopf- und Brustkrebs; für die übrigen Krebsarten fand sich kein Zusammenhang.
Zusammenfassung
Two-sample Mendelian Randomization zu Cannabis-Gebrauch und 9 Krebsarten (GWAS-Daten, europäische Abstammung). Signifikanter kausaler Zusammenhang für Zervixkarzinom (OR=1.001265, 95% CI 1.000375–1.002155, p=0.0053); suggestive Evidenz für Larynxkarzinom (OR=1.000350, p=0.0336) und Brustkrebs (OR=1.003741, p=0.0467). Keine Assoziation mit Melanom, Kolorektal-, Oral-, Ösophagus-Karzinom oder Gliom.
P
PopulationEuropäische Populationen aus GWAS-Meta-Analysen und UK Biobank-Kohorte für 9 Krebsentitäten (Zervix-, Brust-, Kehlkopf-, Kolorektal-, Haut-, Mund-, Oropharynx-, Ösophaguskarzinom, Gliom)
I
InterventionCannabis-Konsum (genetische Instrumente aus GWAS, P<5E-06)
C
KontrolleNicht-Cannabis-Konsum (genetische Instrumente als Kontrolle in MR-Design)
O
OutcomeSignifikanter kausaler Zusammenhang für Zervixkarzinom (OR=1.001265, 95%CI 1.000375-1.002155, P=0.0053); suggestive Evidenz für Kehlkopf- und Brustkrebs; keine Assoziation für andere Krebsentitäten
Vertrauen in die Evidenz
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Herabgestuft wegen
Publikationsbias
Qualitätsprofil
Größe
—
Verblindung
—
Effektstärke
—
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
Purpose: Cannabis use is increasing legally worldwide, while its impact on cancer risk is unclear. This study was performed to investigate the relationship between cannabis use and the risk of several types of cancer.
Methods: We conducted a two-sample Mendelian randomization (MR) study to explore the causality of cannabis use on 9 site-specific types of cancer including breast cancer, cervical cancer, melanoma, colorectal cancer, laryngeal cancer, oral cancer, oropharyngeal cancer, esophageal cancer, and glioma. Genome-wide significant genetic instruments (P < 5E-06) for cannabis use were extracted from a large-scale genome-wide association meta-analysis of European ancestry, whereas cancer genetic instruments were extracted from the UK Biobank (UKB) cohort and GliomaScan consortium in the OpenGWAS database. The inverse-variance weighted (IVW) was considered the main method for MR analysis, and sensitivity analyses including MR-Egger, weighted median, MR pleiotropy residual sum, and outlier test (MR-PRESSO) were conducted to evaluate the robustness of the results.
Results: Cannabis use was a significant promoting factor for cervical cancer (OR = 1.001265, 95% CI 1.000375-1.002155, P = 0.0053). And we also detected suggestive evidence of the causality of cannabis use on laryngeal cancer (OR = 1.000350, 95% CI 1.000027-1.000672, P = 0.0336) and breast cancer (OR = 1.003741, 95% CI 1.000052-1.007442, P = 0.0467). No evidence of a causal association of cannabis use with other site-specific types of cancer was detected. Additionally, no pleiotropy or heterogeneity was found in the sensitivity analysis.
Conclusion: This study indicates a causative association of cannabis use on cervical cancer, while cannabis use may increase the odds of breast cancer and laryngeal cancer, which require further evaluation in large-scale population-based studies.
„Was dem Handeln im Weg steht, wird zum Weg.“